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The latency-associated nuclear antigen (LANA) is central to the maintenance of Kaposi’s sarcoma-associ-
ated herpesvirus (KSHV) and to the survival of KSHV-carrying tumor cells. In an effort to identify interaction
partners of LANA, we purified authentic high-molecular-weight complexes of LANA by conventional chroma-
tography followed by immunoprecipitation from the BC-3 cell line. This is the first analysis of LANA-
interacting partners that is not based on forced ectopic expression of LANA. Subsequent tandem mass
spectrometry (MS/MS) analysis identified many of the known LANA-interacting proteins. We confirmed
LANA’s interactions with histones. Three classes of proteins survived our stringent four-step purification
procedure (size, heparin, anion, and immunoaffinity chromatography): two heat shock proteins (Hsp70 and
Hsp96 precursor), signal recognition particle 72 (SRP72), and 10 different ribosomal proteins. These proteins
are likely involved in structural interactions within LANA high-molecular-weight complexes. Here, we show
that ribosomal protein S6 (RPS6) interacts with LANA. This interaction is mediated by the N-terminal domain
of LANA and does not require DNA or RNA. Depletion of RPS6 from primary effusion lymphoma (PEL) cells
dramatically decreases the half-life of full-length LANA. The fact that RPS6 has a well-established nuclear
function beyond its role in ribosome assembly suggests that RPS6 (and by extension other ribosomal proteins)
contributes to the extraordinary stability of LANA.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is associ-
ated with primary effusion lymphoma (PEL), Kaposi’s sarcoma
(KS), and the plasmablastic variant of multicentric Castleman
disease (MCD) (6, 8, 73). Like other herpesviruses, KSHV
exhibits two distinct phases in its life cycle: latent episomal
persistence and lytic replication. During latent infection, only a
small subset of viral proteins is expressed (7, 12–14, 28, 56, 74,
83). One of these is the KSHV latency-associated nuclear an-
tigen (LANA). It is encoded by open reading frame 73
(ORF73) and consistently expressed in all latently infected
cells. LANA is necessary and sufficient for viral episome per-
sistence and faithful partition of the latent KSHV genome.
LANA tethers the viral plasmid to cellular chromosomes (1, 2,
24, 25). However, this is not the only function of LANA.
LANA is a multifunctional protein. Many proteins bind to
LANA. These can be grouped according to their presumed
functions. (i) Barbera et al. demonstrated that the N terminus
of LANA docks onto cellular chromosomes by directly binding
to the folded regions of histones H2A and H2B to mediate
nucleosome attachment (3). Both histones H2A and H2B were
necessary for LANA to bind nucleosomes. (ii) Robertson and
colleagues found that LANA also binds histone H1 as well as
other proteins involved in the structural remodeling of DNA
(77). (iii) Cellular replication and replication licensing factors
can bind to LANA (45, 75, 78), as well as the chromatin-
modifying factors SAP30, mSin3A, CIR, meCP2, and DEK
(35, 36). Further binding partners have been described (5, 71).
These include Ku70, Ku80, and PARP-1. (iv) Cellular tran-
scription factors can bind to LANA, such as Sp-1 (33), RBP-j
(also known as CSL) (40), glycogen synthase kinase 3 (GSK-
3) (21), CBP/p300 and ATF4/CREB2 (43), Ring3 (48, 53, 60,
79), and KSHV Rta/orf50 (41). (iv) LANA binds to Rb (61) as
well as to p53 (18, 80). The LANA-p53 complex can be de-
stroyed by the mdm-2/p53 interaction inhibitor nutlin (9, 58,
67), which leads to p53-dependent apoptosis in PEL. Because
of its ability to decorate host chromosomes, LANA can induce
chromosome instability phenotypes that are akin to p53 inac-
tivation (54, 70).
Here we find a new binding partner of LANA: the ribosomal
protein S6 (RPS6). RPS6 (32 kDa) is a component of the 40S
ribosomal subunit and the major phosphoprotein of the ribo-
some (59). The phosphorylation sites in RPS6 have been
mapped to five clustered residues: Ser235, Ser236, Ser240,
Ser244, and Ser247 (34, 66). RPS6 phosphorylation and func-
tion are highly regulated. RPS6 has been implicated in the
regulation of translational initiation and protein synthesis in
response to extracellular stimuli such as TRAIL and gamma
interferon (IFN-), as well as upon activation of the phospha-
tidylinositol 3-kinase (PI3K)–Akt–mTOR pathway (4, 38, 42).
Ribosome biogenesis and translation are regulated at multiple
levels and are associated with cell growth and proliferation
(65). Several ribosomal proteins are overexpressed in a variety
of tumors. It remains to be determined whether this represents
a cause or a consequence of tumor formation (66). Phosphor-
ylated RPS6 is a biomarker for mTOR-targeted therapy in
sarcoma (26), including KS (unpublished data). RPS6 is con-
sistently phosphorylated in PEL and KS (72). Importantly, and
perhaps underappreciated, the RPS6 protein is both cytoplas-
mic and nuclear localized (57). The RPS6 protein consists of
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three modules: a nuclear localization signal (NLS), a nucleolar
binding sequence (Nobis), and the C-terminal serine cluster of
phosphorylation sites, which is evolutionarily conserved (38,
44, 68).
We find that RPS6 exists in complex with the KSHV LANA
protein in PEL. This complex was stable after multiple chro-
matographic purification steps and was resistant to DNase and
RNase treatment. This interaction suggests a new role for
LANA in protein translation and ribosome biogenesis and vice
versa a role for RPS6 in LANA function and, as we report
here, LANA protein stability.
MATERIALS AND METHODS
Cell culture. BC-3 cells were cultured in RPMI 1640 medium (Cellgro, Inc.)
containing 2 mM L-glutamine, 10% fetal bovine serum, penicillin G (100 U/ml),
and streptomycin sulfate (100 g/ml) and supplemented with 0.05 mM 2-mer-
captoethanol (Sigma, Inc.), 0.075% sodium bicarbonate (Life Technologies,
Inc.), and 1 U/ml human interleukin-6 (IL-6) (Roche, Inc.). HeLa cells (Amer-
ican Tissue Culture Collection [ATCC] no. CCL-2) were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS). All
cells were grown at 37°C under 5% CO2 atmosphere.
Antibodies. Anti-LANA monoclonal antibody (MAb) LN53 was purchased
from Advanced Biotechnology, Inc., and used at a dilution of 1:2,000. Anti-
LANA polyclonal rabbit antiserum was raised against the LANA repeat region
(9). The additional antibodies used were as follows: anti-p53 MAb DO1 (1:2,000)
(Santa Cruz, Inc.) and anti-phospho RPS6 rabbit antiserum (1:2,000 Ser 235/236
and 1:2,000 Ser 240/244), as well as total anti-RPS6 antibody (1:2,000) (Cell
Signaling), anti--actin mouse MAb ((1:3,000) (Sigma, Inc.), and anti-p21 mouse
MAb (1:1,000) (Santa Cruz). Mouse anti-RPL11 (clone 3a4a7) was from Invit-
rogen, Inc., and antihemagglutinin (anti-HA; clone HA-7) and anti-FLAG (clone
M2) were from Sigma, Inc.
Plasmids. The human RPS6 ORF was PCR amplified from RpS6-FLAG-VRP
(a gift from R. Johnston [50]). To construct HA-tagged RPS6, we fused RPS6
with HA-tagged sequence (YPYDVPDYA) into plasmid pcDNA3 (Invitrogen,
Inc.) at the N-terminal portion of RPS6 ORF (pDD1902). This procedure used
the primers F1 (5-GCATACCCATACGATGTTCCAGATTACGCTCTGAAC
ATCTCCTTCCC; HA tag is underlined) and F2 (5-CGACCCAAGCTTACC
ATGGCATACCCATACGATGTTCC), which incorporates a HindIII site (un-
derlined), as well as the common reverse primer R (5-GTCACGGGATCCCG
TTATTTCTGACTGGATTC), which incorporates a BamHI site (underlined).
The full-length plasmid of FLAG-LANA was a gift from D. Hayward (20). A
series of mutants (amino acids [aa] 1 to 930, 1 to 428, 1 to 329, 330 to 1162, and
930 to 1162) of LANA were individually constructed into the pFLAG-CMV
plasmid (Invitrogen, Inc.) using HindIII and EcoRI sites to yield pDD1926,
pDD1927, pDD1928, pDD1929, and pDD1931, respectively.
Chromatography and MS/MS. BC-3 cells (5  109) were harvested and the
nuclear extracts were obtained as described previously (11). The supernatant was
loaded onto a Sepharose 6B column (Sigma, Inc.) and washed with 0.1 M KCl in
buffer D (20 mM HEPES-KOH [pH 7.9], 10% glycerol, 0.1 M KCl, 0.2 mM
EDTA, 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 0.5 mM dithiothreitol
[DTT], 0.5% cocktail protein inhibitor). Sepharose 6B was used not as an affinity
resin, but as a sizing matrix for high-molecular-weight complexes. This choice
was based on the initial use of Sepharose 6B prior to its discovery as an affinity
resin. When using 6B resin to separate large protein complexes such as LANA,
multimers (220 kDa  4) and multimer-containing complexes elute close to the
void volume, monomers, and broken complexes tend to be retained. Column
fractions containing LANA were collected and loaded onto Hiprep 16/10 heparin
FF column (Amersham, Inc.), followed by a wash with 20 column volumes of 0.2
M KCl in buffer D and elution with 0.5 M KCl in buffer D. The fractions were
then loaded onto a Mono-Q column (Sigma, Inc.). We collected two peaks at 0.4
M buffer D and 0.7 M KCl in buffer D. Immunoprecipitation with anti-LANA
antibody (LN53; ABI, Inc.) was from a the second peak as described previously
(9). Proteins were resolved by 8 to 16% gradient SDS-PAGE and stained with
Coomassie blue (Bio-Rad, Inc.). Visible bands were cut and further subjected to
mass spectrometry at the University of North Carolina—Chapel Hill core facility.
They were further digested with trypsin, and the resulting peptides were analyzed
on an ABI 4800 matrix-assisted laser desorption ionization–tandem time of flight
(MALDI TOF/TOF) MS analyzer. MS spectra were executed in a reflector
positive-ion mode, with a mass range of 700 to 4,000 Da, and with a total number
of shots/spectrum of 1,250. MS/MS spectra were executed in a positive-ion mode
at 2 kV and with a total number of shots/spectrum of 1,350 or less. The peptides
with signal/noise ratio above 20 at the MS mode were selected for MS/MS run;
a maximum of 45 MS/MS was allowed per spot. The precursor mass window was
200 relative resolution (fwhm). All spectra were searched against taxonomy,
NCBInr database, using GPS Explorer software version 3.6 (ABI) and the Mas-
cot (MatrixScience) search engine. Variable modifications included oxidation
(M). Mass tolerance was 80 ppm for precursor ions and 0.5 Da for fragment ions;
two missed cleavages were allowed.
Immunoprecipitation and Western blot analysis. For immunoprecipitation,
the collected transfected cells were lysed with cold radioimmunoprecipitation
assay (RIPA) buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl [pH 8.0], 1 mM
EDTA, 0.5 mM DTT, 0.5 mM PMSF, 0.5% cocktail protein inhibitor [Sigma,
Inc.]) for 20 min. After centrifugation at 12,000  g, the supernatants (or column
fractions where indicated) were precleared with 30 l protein G-agarose beads
(Sigma) for 2 h and then incubated first with the appropriate antibodies over-
night and then with 40 l of protein G-agarose beads with gentle rotation for 2 h
at 4°C. The beads were collected by centrifugation at 5,000  g for 1 min, and the
pellets were washed four times with ice-cold RIPA buffer.
For immunoprecipitation of FLAG-tagged proteins, the cell lysates were in-
cubated with 30 l EZview anti-FLAG M2 affinity resin (Sigma, Inc.) for 4 h or
overnight at 4°C. FLAG-tagged proteins were eluted by incubation with 50 l of
150 g/ml 3 FLAG peptide (catalog no. F 4799; Sigma, Inc.) in Tris-buffered
saline (TBS; 10 mM Tris-HCl, 100 mM NaCl [pH 8.0]) for 1 h at 4°C. Samples
were then added to 5 SDS protein sample buffer (300 mM Tris-HCl [pH 8.0]),
10% SDS, 25% -mercaptoethanol, 0.1% bromophenol blue, 50% glycerol) and
analyzed with 8 to 16% SDS-PAGE Tris-HCl gel, and transferred to Hybond P
membranes (GE Life Sciences, Inc.). After blocking with 5% nonfat milk, the
membrane was incubated with the corresponding primary antibody in TBS-
Tween (TBST; 10 mM Tris-HCl [pH 8.0], 100 mM NaCl, 0.1% Tween 20) plus
5% nonfat dry milk and washed three times for 10 min with TBST. After
incubation with a horseradish peroxidase-linked secondary antibody (1:3,000)
(VWR, Inc.), an enhanced chemiluminescence system (Thermo Scientific, Inc.)
was used for detection via X-ray film (Genesee, Inc., catalog no. 30-101) for
visualization.
ChIP assay. For chromatin immunoprecipitation (ChIP), BC-3 cells (1  106)
were cross-linked with formaldehyde at a final concentration of 1% for 10 min at
37°C. After being washed with phosphate-buffered saline (PBS) twice, cellular
chromatin was sheared to approximately 500 bp using the Sonifier 450 sonicator
(Branson output, 3.0; duty cycle, 30%) on ice four times for 30 s each. Immu-
noprecipitation, washing, and recovery of bound DNA were performed accord-
ing to the manufacturer’s protocol (Upstate Biotechnology, Inc.). The antibodies
used were mouse monoclonal anti-LANA (LN53; ABI, Inc.) at 1 g/reaction and
anti-RPS6 (54D2; Cell Signaling, Inc.) at 1 g/reaction. Mouse IgG at 1 g/
reaction was used as a control. Equal amounts of DNA pellets were used for
PCR (Promega, Inc., catalog no. M7122). The forward primer for the LANA
promoter (LANAp) was 5-AGATCGCAGACACTGAAACGCTGA-3, and
the reverse primer was 5-GCAAAGCAGACACGCCTTCTTCAGT-3. -Actin
was used for a control with forward primer 5-GGCATCGTGATGGACTCC
G-3 and reverse primer 5-GCTGGAAGGTGGACAGCGA-3.
shRNA knockdown of RPS6. A set of pLKO.1 lentiviral vectors for RPS6
(NM_001010) were obtained from Open Biosystems/Thermo, Inc. The recon-
structed lentiviruses were produced by the Lenti-shRNA Core Facility of Uni-
versity of North Carolina. BC-3 cells (5  105) were grown in six-well plates,
infected with either of the respective lentiviruses (titer of 106 IU/ml) and Poly-
brene at a final concentration of 10 g/ml, and incubated at 37°C for 6 h. After
infection for 6 h, BC-3 cell medium was replaced with fresh RPMI 1640 supple-
mented with 10% fetal bovine serum. After 24 h, puromycin (5 g/ml) was added
to the medium, and cells were harvested 3 or 4 days after transfection. The
numbers of viable cells were counted throughout the time course. Lentivirus
short hairpin RNA (shRNA) against green fluorescent protein (GFP) or un-
treated BC-3 cells were used as a control.
Reporter assays. SLK cells (1  105 to 5  105) were seeded in 12-well plates
at 37°C. After 24 h, the cells were transfected with reporter (pDD83) (62) and
effector plasmids (pDD104 expressing LANA and pDD1902 expressing RPS6),
using 7.5 l Superfect reagent (Qiagen, Inc.) according to previously published
methods (29). pcDNA3 (Invitrogen, Inc.) was used to adjust total DNA concen-
tration, and the medium was changed 24 h after transfection. The cells were
harvested 48 h posttransfection, washed twice with ice-cold PBS, and lysed in 200
l of 1 reporter lysis buffer, and then the luciferase substrate was added
(Promega, Inc.). Luciferase activity was quantified via a luminometer (Fluorstar
Optima; BMG, Inc.). The background (pGL3 basic vector) activity was below 100
relative light units (RLU). The transfection efficiencies were normalized by
cotransfecting a lacZ expression plasmid (pDD173) and analyzing -galacto-
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sidase activity using the Galacto-Light plus -galactosidase assay kit (Applied
Biosystems, Inc.). The data series represents one of three transfections. We used
robust regression to establish a linear dose response relationship (64).
RESULTS
Identification of nuclear LANA binding proteins under
physiological conditions. During viral latency in KSHV-in-
fected PEL cells, LANA is expected to interact with multiple
cellular proteins. We hypothesized that there exist multiple
distinct complexes of LANA and one or more associated cel-
lular proteins, each for the different physiological functions of
LANA. Because of their different enzymatic functions, these
complexes are expected to have different biochemical proper-
ties. Since these complexes may have different biochemical
properties, they are enriched by different biochemical purifi-
cation procedures. Because LANA has a distinct domain struc-
ture with the two terminal globular domains separated by a
large variable, and for the most part dispensable repeat region,
prior studies (3, 31) used domain-based baits rather than the
whole protein to identify interaction partners.
To identify the components of LANA complexes that bound
to the whole LANA protein in latently infected cells, we first
prepared nuclear extracts from BC-3 cells and then used mul-
tiple steps of chromatographic enrichment (Sepharose, hepa-
rin FF, and Mono-Q column) prior to immunoprecipitation
with a LANA-specific monoclonal antibody. Figure 1A dia-
grams our purification strategy. This approach requires LANA-
interacting proteins to be stably bound to LANA and the
interaction to withstand high-salt- and low-protein-concentra-
tion conditions. Many transcription factors were initially iden-
tified by this approach (11), and we previously used it to
discern different LANA-p53 complexes (9). Coimmunoprecipi-
tation was then used to identify the proteins bound to LANA
either after chromatography on just a size exclusion column
and heparin column (Table 1) or after chromatography that
included an additional ion-exchange column (Table 2). The
immunoprecipitates were ultimately analyzed by 8 to 16% gra-
dient SDS-PAGE (Fig. 1B and C), and individual bands were
subjected to tandem MS (MS/MS) analysis.
We identified 48 proteins that coimmunoprecipitated with
LANA after heparin fractionation (Table 1). Twenty-two
(46%) were previously found in MS/MS screens for mutant
LANA-associated proteins. These included the previously
identified histone H2A. Ten (21%) of the bands corresponded
to ribosomal proteins, and the remainder corresponded to
novel potential LANA interaction partners and IgG. We did
not subject bands of the expected molecular weight of LANA
to MS/MS for economic reasons. Twenty-one proteins re-
mained bound to LANA after an additional MonoQ purifica-
tion step (Table 2). We recovered LANA itself (131,268 kDa),
as expected, as well as IgG() light chain (8,496 kDa). We
recovered multiple forms of myosin, actin, and tubulin. Al-
though it seems unlikely that these are bound to LANA, an-
other KSHV protein, LANA-2, has been shown to interact
with tubulin and to thereby affect paclitaxel resistance of PEL
(51).
We recovered heat shock protein 96 (Hsp96) precursor
(90,138 kDa) and Hsp70 (70,854 kDa) from LANA coimmu-
noprecipitates, as well as the signal recognition particle SRP72
(74,560 kDa). The significance of these results is under inves-
tigation, although it seems plausible that LANA binds to Hsps
analogous to the Epstein-Barr virus (EBV) EBNA5/EBNA-LP
(16, 23, 32, 46) and EBV EBNA3A (81) proteins binding Hsps.
We recovered multiple ribosomal proteins that coimmuno-
precipitated with LANA. This mirrors earlier results by Kaul et
al. (31). However, we did not recover exactly the same ribo-
somal proteins. Our collection of copurified ribosomal proteins
is characterized by proteins with predominantly basic isoelec-
tric points (pIs). With the exception of P0, the other 10 ribo-
somal proteins have predicted pIs of 9.7. In contrast, full-
length LANA has a predicted pI of 3.9. Hence, it seems
unlikely that the ribosomal proteins would copurify over
FIG. 1. Purification and identification of LANA binding proteins. (A) A schematic of the procedures used to purify LANA complexes. (B and
C) SDS-PAGE of the 8 to 16% gradient gel stained with Coomassie blue. Samples were eluted following immunoprecipitation with rat anti-LANA
(-LANA) antibody from heparin fractions (B) or after additional ion-exchange (MonoQ) purification (C). The isolated protein bands of
complexes are denoted with black arrows (LANA, S6, and IgG). Co-IP, coimmunoprecipitation; M, molecular mass markers.
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TABLE 1. LANA binding proteins with anti-LANA immunoprecipitation after purification by heparin column chromatographya
Lane Database identificationno. Protein name
Size





1 AAP69525 Protein kinase, DNA activated 4,128 468,787.9 49 195 34
2 BAD52438 Nonerythrocytic spectrin  2,452 282,108 44 155
3 Q53R99 Hypothetical protein SPTBN1 2,314 268,549 48 494
4 MYH9_HUMAN Myosin-9 (myosin heavy chain, IIa) 1,960 226,260.5 58 732 34
5 Q9HBD4_HUMAN SMARCA4 isoform 2, BRG1 1,679 188,030.8 28 242 74
6 A54854 Ras GTPase-activating protein-related
protein
NAc 189,133.8 31 183
7 Q5T5X0 Eukaryotic translation initiation factor 3 1,382 166,468.3 42 120
8 AAB41498 Alpha II spectrin  2,477 284,890.5 55 556 34
9 AAB48855 RNA helicase A 1,279 141,979.7 20 158 74
10 Q75M86 Hypothetical protein GTF2I 978 110,211 35 527
11 Q59FF0 EBNA-2 coactivator variant 964 107,366.3 32 564
12 ILF3_HUMAN Interleukin enhancer binding 894 95,279.1 20 370 27
13 A46302 PTB-associated splicing factor NA 76,101.6 26 441
14 AAH27713 Heterogeneous nuclear
ribonucleoprotein
804 90,235.8 23 159
Q86VG2 Splicing factor 707 76,140.7 15 116 27
Q2VPJ6 Hsp90AA1 protein 585 68,328.8 13 75
15 AAB48826 BTK-associated protein 135 957 107,812 25 204
16 CAH10627 HSM803020 NID—Homo sapiens 652 72,496.1 17 151
17 Q59GX6 DEAD/H (Asp-Glu-Ala-Asp/His) box 674 74,532.7 20 180 74
18 JC1087 RNA helicase, ATP-dependent NA 69,104.7 19 249 34, 74
19 A25707 U1 snRNP 70K protein NA 70,039.5 17 121
20 Q8TBR3 Fusion involved in t(12;16) in
malignant liposarcoma	
526 53,367.8 12 175 74
21 Q59H57 Fusion (involved in t(12;16) in
malignant liposarcoma	
300 31,974.3 14 294 74
22 Q8TBR3 Fusion involved in t(12;16) in
malignant liposarcoma	
526 53,367.8 11 155 74
23 AAQ05673 Ig heavy chain variable region, VH3 120 13,308.5 4 77 IgG
24 AAA35750 DNA-binding protein B 364 39,953.8 16 223
Q53HR5 Eukaryotic translation EF1 426 50,093.1 12 90 27
25 AAH12854 ACTB protein 360 40,194.1 24 899
26 Q53FG3 Interleukin enhancer binding 390 43,021.2 14 255
27 CAF06488 AX961958 NID—Homo sapiens 285 30,569.1 12 214
AAH04383 Polypyrimidine tract binding protein 531 57,185.6 5 118
28 Q53RW7 Hypothetical protein HNRPA3 378 39,570.6 14 244 74
29 B34504 Heteronuclear ribonucleoprotein B1 NA 37,406.7 22 603 81
30 Q2HJ60 Heteronuclear ribonucleoproteins A2 341 35,983.9 21 766 74
31 B34504 Heteronuclear ribonucleoprotein A2/B1 NA 37,406.7 18 595 74
32 Q3MIB7 HNRPA1 protein 267 29,368.2 22 781 74
34 AAH12197 Ribosomal protein L8 257 27,993.3 14 69 ribo
35 RL7A_HUMAN 60S ribosomal protein L7a 266 29,846 17 200 ribo
36 Q3KQU0 RPL7 protein 318 36,998.8 24 213 ribo
Q53HV1 Ribosomal protein S4 263 29,560 12 134 ribo
37 I38049 MUC18 precursor NA 71,748.7 14 84
Q5JR95 Ribosomal protein S8 188 21,866 9 80 ribo
38 CAE93910 AX887985 NID—Homo sapiens 209 25,112.9 16 193
39 RL10_HUMAN 60S ribosomal protein L10 214 24,429.8 19 261 ribo
RL13A_HUMAN 60S ribosomal protein L13a 203 23,431.3 15 124 ribo
40 RL18_HUMAN 60S ribosomal protein L18 188 21,490 12 115 ribo
41 RS9_HUMAN 40S ribosomal protein S9b 194 22,446.5 13 177 34
S55916 Ribosomal protein S5 NA 22,762.9 8 125 ribo
42 MLRM_HUMAN Myosin regulatory light chain 2 171 19,650.4 7 214
AAB94895 60S ribosomal protein L12 129 14,332.8 5 100 ribo
43 MLRM_HUMAN Myosin regulatory light chain 2 171 19,650.4 7 272
44 RS13_BOVIN 40S ribosomal protein S13 151 17,080.6 8 150 ribo
Q9BQQ5 Ribosomal protein L27 106 12,007.4 5 109 ribo
R3RT18 Ribosomal protein S18 NA 17,707.9 13 108 34
45 MOHU6 M Myosin alkali light chain 6 NA 16,919.1 8 193
46 H2A1A_HUMAN Histone H2A type 1-A (H2A/r) 131 14,093.9 5 99 4, 34
47 R3HU12 Ribosomal protein S12, cytosolic NA 14,516.5 2 86 ribo
48 S55054 Sm protein G—human NA 8,490.4 5 75
a In each case, the highest-scoring hit is shown.
b Previously published in the reference(s) indicated. IgG refers to human IgG, and ribo refers to ribosomal components.
c NA, not available.
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charge-based separation columns (heparin and MonoQ) if they
were not tightly bound to the LANA protein.
It may at first seem counterintuitive that ribosomal subunit
proteins would bind to a nuclear transcription factor, such as
LANA. However, ribosomal proteins are not exclusively cyto-
plasmic: some such as RPS6 shuttle in and out of the nucleus
and accumulate in nuclear and nucleolar bodies (76). We fo-
cused our initial efforts on validating the interaction between
LANA and RPS6 because of its known nuclear localization,
because of the availability of highly specific reagents, and be-
cause the distribution of MS/MS peptide coverage made it
unlikely that RPS6 was incorrectly identified (Fig. 2).
LANA interacts with RPS6. To validate the LANA-RPS6
interaction, we used nuclear extract of BC-3 cells and con-
ducted the reciprocal immunoprecipitation using an anti-RPS6
antibody followed by Western blotting with anti-LANA anti-
body. LANA was associated with RPS6 in the nuclear extract
prior to any purification steps (Fig. 2A, lanes 1 and 2).
Since ribosomal proteins like RPS6 are associated with
rRNA (19), and since LANA may have nonspecific, as well as
sequence-specific nucleic acid-binding capabilities, we exam-
ined the hypothesis that the LANA-RPS6 interaction was de-
pendent on copurifying nucleic acids. We used RNase A and
DNase I to digest nucleic acids in the partially purified LANA-
positive heparin fractions prior to immunoprecipitation with
anti-RPS6 antibody. Despite nuclease digestion, LANA still
interacted with RPS6 in this assay (Fig. 2A, lanes 3 to 6).
To further investigate the specificity of the LANA-RPS6
interaction, we conducted immunoprecipitation with anti-
RPL11 antibody (i.e., a random ribosomal protein that was not
found in our MS/MS profiling) (Fig. 2B). We did not observe
any interaction between LANA and RPL11, which supports
the notion that the LANA-RPS6 interaction was specific and
not the result of whole ribosomes binding to LANA multimers
or the nonspecific anti-LANA antibody.
Next, we used the FLAG-tagged fusion protein of LANA to
detect the interaction with a HA-tagged protein of RPS6 in
cotransfected cells. This experiment confirms specificity and
also demonstrates that the LANA-RPS6 interaction is inde-
pendent of other KSHV proteins. First we generated a full-
length HA-tagged version of RPS6 and cotransfected it with a
FLAG-tagged version of full-length LANA. Using a FLAG-
tagged LANA, rather than anti-LANA antibody, avoids the
potential for nonspecific activity of the anti-LANA monoclonal
antibody LN53. Using tag-specific antibodies for immunopre-
cipitation and Western blotting, we found that LANA coim-
munoprecipitated with RPS6 and that RPS6 coimmunopre-
cipitated with LANA after both proteins were transiently
transfected into HeLa cells (Fig. 3A). This demonstrates that
LANA and RPS6 interact in the absence of other KSHV viral
proteins.
To determine which domain of LANA interacts with RPS6,
a series of LANA mutants were constructed with a FLAG tag
fused to the N terminus of LANA. We also constructed RPS6
with an HA tag fused to the N terminus of RPS6 (Fig. 3B).
Cotransfection of HA-tagged RPS6 and different FLAG-
tagged LANA mutants into HeLa cells indicated that the N-
terminal portion of LANA (aa 1 to 329), excluding the DE
repeats, represents the shortest fragment that could still inter-
act with RPS6 (Fig. 3B). Neither the C terminus nor the re-
peat-rich central domain of LANA interacted with RPS6.
In sum, we have validated the LANA-RPS6 interaction by
multiple independent means: (i) immunoprecipitation with
anti-LANA monoclonal antibody coprecipitates RPS6 at phys-
iological levels in BC-3 cells, (ii) immunoprecipitation with
anti-RPS6 antibody coprecipitates LANA at physiological lev-
els in BC-3 cells, (iii) cotransfection and coimmunoprecipita-
tion with different artificial epitopes (tags) show a complex of
both proteins in the absence of other viral proteins, and (iv) the
LANA N terminus (but not the central region or C terminus)
is sufficient to bind to RPS6.
TABLE 2. LANA binding proteins with anti-LANA precipitation after purification by heparin and anion-exchange column chromatography
Lane Database identificationno. Protein name
Size
(no. of aa) Mol mass (Da)
No. of peptides
(hits) MS/MS score pI
1 Q60FE2 Myosin 1,960 226,391.6 40 488 5.5
2 Q9QR71_HHV8 LANA 1,129 131,267.9 12 264 3.9
3 AAA59888 Myosin 1,337 154,265.7 30 492 5.7
4 AAK74072 Hsp96 precursor 782 90,138.1 18 208 4.73
5 AAC97490 SRP72 671 74,560 12 203 9.31
6 A27077 Hsp70 646 70,854.2 24 662 5.62
7 AAH04949 Tubulin 449 49,863.5 13 464 4.96
8 AAH20946 Tubulin 444 49,639.9 17 715 4.75
9 AAH20946 Tubulin 444 49,639.9 14 208 4.75
10 RL4_HUMAN Ribosomal L4 (L1) 427 47,536.4 15 91 11.07
11 Q96HG5 Actin 368 40,978.4 22 1,100 5.56
12 AAH01127 Ribosomal P0 317 34,252.7 17 378 5.42
13 Q6NXR8 Ribosomal S3A 264 29,955.8 13 183 9.75
14 AAH09427 Ribosomal S6 247 28,403.8 8 128 10.84
15 RL7A_HUMAN Ribosomal L7a 266 29,846 12 129 10.61
16 Q53HV1 Ribosomal S4 263 29,560 13 159 10.11
17 S23753 Ribosomal L13 211 24,276.5 8 129 11.69
18 CAC94454 IgG() 78 84,96.1 2 168 5.55
19 RL10_HUMAN Ribosomal L10 214 24,429.8 13 381 10.11
20 RS13_BOVIN Ribosomal S13 151 17,080.6 10 358 10.53
21 R3HU16 Ribosomal S16 146 16,435 8 192 10.42
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RPS6 associated with LANA on LANAp. We had shown
earlier that LANA could bind to a LANA-responsive DNA
element within its promoter and thereby autoactivate the
LANA promoter (LANAp) (30). We had found that the bind-
ing interaction between the LANA protein and this single
DNA element is considerably weaker than the interaction be-
tween LANA and the multimerized, canonical LANA binding
sites in the viral terminal repeats (TRs). Thus, chromatin im-
munoprecipitation analysis (ChIP) analysis of the LANA pro-
moter represents a more stringent assay for the purpose of
demonstrating a trimeric LANA-RBS6-DNA complex than
the TR. The LANA promoter also provides for a better PCR
target for ChIP, whereas we were unable to PCR across the
LANA binding sites within the GC-rich terminal repeat re-
gions (data not shown). Using ChiP, we asked whether RPS6
was present in the LANA-LANA promoter complex in vivo.
After cross-linking with 1% formaldehyde, the sonicated sam-
ples were immunoprecipitated with anti-LANA or anti-RPS6
monoclonal antibodies, respectively, and we PCR amplified
the coprecipitated DNA (Fig. 4A, upper panel). We could
amplify a band of the expected molecular weight for the spe-
cific fragment of the LANA promoter from immune precipi-
tates using anti-LANA as well as anti-RPS6 antibodies, but not
the IgG-negative control. We could not PCR amplify any prod-
uct using primers specific for -actin, which served as a nega-
tive control for nonspecific DNA binding (Fig. 5A, lower
panel). We conclude, by another independent assay, that RPS6
is in a complex with KSHV LANA and that at least some of the
RPS6-LANA complexes are present at the LANA promoter.
By no means do we want to imply that RPS6 is a transcrip-
tion factor. Rather, we use the phenotype of LANA to bind its
cognate DNA as a biochemical assay to verify the RPS6-LANA
interaction. As an alternative readout for the LANAp-LANA-
RPS6 interaction, we modified our established transient trans-
fection assay, using a LANA promoter-luciferase construct as
the reporter. This represents a variant of a mammalian two-
hybrid assay using the LANA DNA binding domain and cog-
nate cis element. Instead of fusing RPS6 to a strong artificial
transactivation domain, we used a statistical measure (dose
dependence under limiting conditions) to validate the LANA-
RPS6 interaction. The LANA promoter is constitutively active.
Cells were cotransfected with the reporter and increasing
amounts of RPS6. We used empty vector to adjust for the total
DNA concentration. The background (pGL3 vector) activity
was below 100 RLU. In the absence of LANA, RPS6 did not
affect promoter activity (Fig. 4B, left panel). This would be
expected since RPS6 is not a transcription factor. Transient
transfection of LANA itself transactivates this LANA pro-
moter report construct, albeit weakly, and we used a subopti-
mal amount of LANA in order to measure the effect of RPS6.
In the presence of cotransfected LANA, RPS6 increased pro-
moter activity (Fig. 4B, right panel). We observed a linear
dose-response curve. Albeit not dramatic, the slope was signif-
icant at P  0.027 using robust linear regression (64). We
interpret the linear dose dependence rather than the overall
fold change as evidence for the interaction between LANA and
RPS6. Clearly RPS6 is not a transcription factor. If we increase
the amount of transfected LANA, the RPS6 becomes negligi-
FIG. 2. Analysis of the interaction between LANA and RPS6 in BC-3 cells. (A) Lanes 1 and 2, nuclear extracts (NE) of BC-3 cells; lanes 3 to
6, samples purified by heparin FF column. Treatments for each lane are as follows: lane 1, 37°C for 30 min and treatment with 500 U/ml DNase
I and100 g/ml RNase A; lane 2, 37°C for 30 min without nuclease treatment; lane 3, 25°C for 20 min without nuclease treatment; lane 4, 35°C
for 20 min with DNase I and RNase; lane 5, 37°C for 20 min with 5 U/l DNase I and 10 U/l RNase; lane 6, 4°C for 30 min without nuclease
treatment. All of the above buffers contain no EDTA. For the immunoprecipitation (IP) assay, lanes 1, 3, 4, and 5 were supplemented with anti-S6
antibodies and lanes 2 and 6 were used as negative controls (IgG only). (B) Immunoprecipitation and Western blot of an irrelevant ribosomal
protein L11 from nuclear extract of BC-3 cells. Shown is input and immunoprecipitation with a control antibody (IgG), with anti-LANA mouse
monoclonal antibody (IP LANA), or anti-RPL11 antibody (IP RPL11) followed by Western blotting with anti-LANA antibody (left) or anti-RPL11
antibody (right). (C) RPS6 protein and the sequences of its corresponding peptides identified by mass spectrometry analysis, shown in a table of
peptides. (D) Alignment of peptides (underlined) with the S6 sequence (GenBank accession no. NP_001001; gene identification [ID] no. 6194 RPS6).
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ble since LANA protein is no longer rate limiting within the
cell.
One possible outcome was that RPS6 would alter overall
LANA protein levels. To test this hypothesis, the experiment
was repeated and LANA and RPS6 levels were determined by
Western blot (Fig. 4C). We observed the expected dose-de-
pendent increase of RPS6 protein levels with increased
amounts of RPS6 expression vector. In contrast, the level of
LANA did not change appreciably. Using LANA’s DNA bind-
ing ability as a novel, independent assay, Fig. 5 verifies that
LANA binds to RPS6.
Reduction of RPS6 protein reduces LANA protein expres-
sion. Since RPS6 was in a complex with LANA, we hypothe-
sized that RPS6 positively supports the translation of LANA
(and perhaps contributes to the extraordinary stability of
LANA). To test this hypothesis under physiological conditions,
BC-3 cells were infected with a series of recombinant shRNA
lentiviruses that target the RPS6 mRNA. One vector (Sh-4)
resulted in marked reduction of RPS6 levels at day 4 after
infection (Fig. 5A) and was selected for further study. Trans-
duction of BC-3 cells with this validated shRNA lentiviral
vector against RPS6, but not an irrelevant (GFP) shRNA len-
tiviral vector led to a reduction of LANA protein steady-state
levels as early as day 3 post-shRNA lentiviral vector transduc-
tion (Fig. 5B). Levels of an unrelated, equally stable protein
(-actin) were not affected (Fig. 5B). Transduction of BC-3
cells with this validated shRNA lentiviral vector against RPS6,
but not an irrelevant (GFP) shRNA lentiviral vector, induced
FIG. 3. Analysis of the interaction of LANA and RPS6 in HeLa
cells after transfection. (A) Coimmunoprecipitation of full-length
FLAG-tagged LANA and HA-tagged S6 after cotransfection into
HeLa cells. After cotransfection, protein extract was immunoprecipi-
tated with the indicated reagents. The lanes represent input, IgG only,
anti-FLAG, and anti-HA (HA). Anti-FLAG antibodies and anti-HA
antibodies were used for Western blot (WB) analysis, as indicated on
the left. (B) Schematic diagram of mutant LANA proteins used. All
segments were fused with FLAG tag at the N terminus of LANA. The
numbers on the right indicate the lane numbers in panel C and the “
”
or “” symbols summarize whether or not an interaction was detected.
(C) Coimmunoprecipitation assay of HA-RPS6 and different mutants
of FLAG-tagged LANA. Anti-FLAG and anti-HA antibodies were
used for immunoprecipitation (IP) or Western blotting (WB) as indi-
cated. Ve, vector.
FIG. 4. Complex of LANA and S6 binds to LANA promoter.
(A) BC-3 cells were cross-linked and sonicated, and chromatin immu-
noprecipitation (IP) was performed with mouse anti-LANA (LN53)
and mouse anti-RPS6 (54D2) monoclonal antibodies. IgG was used as
a control. Inputs were 5% of lysates of each sample. The DNA frag-
ments immunoprecipitated were amplified with the respective primers
for the LANA promoter (LANAp) and -actin. (B) Cotransfection of
LANA and RPS6 into SLK cells increases the activity of a LANA
promoter-luciferase reporter. Relative light units (RLU) are shown on
the y axis, and the amount of S6 plasmid per transfection mixture is
shown on the horizontal axis. All measurements were conducted in
triplicate, and each is shown. The background (pGL3 vector) activity
was below 100 RLU. Also shown are the regression lines (black), which
demonstrate a linear dose dependence of LANA promoter activity on
RPS6. (C) Western blot analysis of SLK cells cotransfected with in-
creasing amounts of HA-tagged RPS6 expression vector in the absence
or presence of LANA. A Western blot for actin is shown as a loading
control.
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levels of p21 and p53 (Fig. 5B). We used p53 as a positive
control to investigate the hypothesis that ablation of RPS6
does not abrogate protein translation in general but results in
a specific cellular signaling event. Disturbing ribosome assem-
bly by ablating RPS6 expression is known to activate p53 (22),
which in turn induces transcription and translation of p21. This
piece of data is consistent with p53 activation, not nonspecific
translation inhibition.
FIG. 5. Analysis after knockout of RPS6. (A) BC-3 cells were transduced with five recombinant lentiviruses (S6 Sh-1 to Sh-5) encoding different
shRNAs directed against RPS6 in six-well plates. shRNAs against GFP-encoding lentivirus and untreated BC-3 cells were used as controls.
Western blot analysis was performed 4 days postransduction using anti-RPS6 (S6) and anti--actin (Actin) antibodies. (B) Western blots were
performed 3 days after knockdown of RPS6 with shRNA no. 4, probing with anti-LANA, anti-p53, anti-p21, and anti--actin antibodies,
respectively, at 3 days postransduction. (C) Proliferation of BC-3 cells was measured at different time points following shRNA-mediated RPS6,
as described above. The number of cells is shown on the y axis, and the time after transduction is shown on the x axis. The cells were not refed
in between time points. (D) Protein stability analysis of LANA. BC-3 cells were transduced with anti-RPS6 (S6 Sh-4) shRNA vector or control
shRNA vector (GFP Sh) and exposed to cycloheximide (CHX) starting at day 3 postransduction, and LANA and actin protein levels were
determined by Western blot analysis at the indicated times (in hours). (E) Protein stability analysis of p53. BC-3 cells were transduced with
anti-RPS6 (S6 Sh-4) shRNA vector or control shRNA vector (GFP Sh) and exposed to cycloheximide and LANA, and actin protein levels were
determined by Western blot analysis at the indicated times (in minutes). (F) Protein stability determination for LANA and p53 (G). The protein
bands in panels D and E were scanned, and band intensities were calculated. The log10 band intensity of the fraction at time zero is shown on the
y axis, and time is shown on the x axis. Lines represent the robust fit of the data.
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Inhibition of RPS6 expression by shRNA inhibited cell pro-
liferation compared to control shRNA lentiviral transduction,
as shown in Fig. 5C. BC-3 cells were transduced on day 0 and
then observed over time without refeeding. These experiments
were conducted at high cell density so as to maximize the
viability of the cells after shRNA transduction. In this experi-
ment, we did add fresh medium after transduction, which
would activate the mTOR pathway and may have changed the
steady-state levels and function of RPS6. At day 1, there was
no statistical difference between RPS6-specific shRNA-treated
and control shRNA-treated cells. On subsequent days, RPS6-
specific shRNA-infected cells exhibited cell death, whereas
control shRNA-treated cells proliferated and remained viable.
In sum, we have shown that RPS6 contributes to LANA pro-
tein levels, but not to actin protein levels, and that this results
in the induction of p53 protein levels. Hence, it is unlikely that
our knockdown of RPS6 resulted in widespread, indiscriminate
translational arrest of protein synthesis. Rather, the impact of
reduced RPS6 levels is most significant upon proteins that are
associated with or deeply dependent upon the presence of
RPS6.
Next, we tested the hypothesis that RPS6 affects the half-life
of LANA. BC-3 cells were transduced with shRNA to RPS6
(S6 Sh-4) or an irrelevant shRNA lentiviral vector (shGFP)
and, starting at day 3 postransduction, treated with cyclohexi-
mide to block novel protein synthesis. After the indicated
times, we probed for LANA levels using Western blotting;
actin was used as a control. In BC-3 cells transduced with the
RPS6 shRNA vector, LANA showed a substantially decreased
half-life (0.60 h) compared to BC-3 cells treated with control
shRNA (28 h) (Fig. 5D and G). This complex requires the N
terminus, since the LANA C terminus alone has a short half-
life—on the order of hours (data not shown). This result is
consistent with a model in which RPS6 is part of a complex that
is responsible for the well-established, unusually long half-life
(on the order of days) of the LANA protein. At the same time
p53 was stabilized (Fig. 5E and G). In BC-3 cells transduced
with the RPS6 shRNA vector, p53 exhibited a slighly increased
half-life (8.8 h) compared to BC-3 cells treated with control
shRNA (2.3 h). This is consistent with the activation of p53 and
increased steady-state levels and the induction of p21 (Fig.
5B). In sum, these experiments demonstrate that RPS6 con-
tributes to the stability and overall level of LANA in PEL cells.
DISCUSSION
LANA is a multifunctional protein, as is RPS6. Here, we
find that both proteins exist in a complex together in KSHV
latently infected PEL cells. Both LANA and RPS6 bind to
each other in cotransfection experiments in the absence of
other viral proteins. Our data reveal that the LANA N-termi-
nal domain mediates this interaction and that this interaction is
resistant to nuclease digestion and therefore independent of
rRNA. Furthermore, we found that RPS6 is present in RPS6-
LANA-DNA complexes on the LANA promoter and that
shRNA-mediated knockdown of RPS6 is associated with a
reduction in LANA protein levels and in LANA protein half-
life. This implicates RPS6 in the translation and/or stability of
KSHV LANA.
LANA is an extraordinarily stable protein with an estimated
half-life of several days (39). The biochemical mechanism for
its stability is unknown. Therefore, it is conceivable that RPS6
can contribute to LANA stability. RPS6 is a very dynamic
protein. It is synthesized in the cytoplasm and then imported
back into the nucleolus, where it assembles into the pre-40S
ribosomal subunit. These complexes are then extruded into the
nucleus proper and then into the cytoplasm. The nuclear im-
port of RPS6 is mediated by three NLSs, and the nuclear
export of RPS6 is dependent on a nuclear export signal (NES)
and CRM1 (38, 44, 49, 68). CRM1-dependent nuclear export
can be specifically inhibited by the pharmacological compound
leptomycin B (LMB). LMB interacts with CRM1 and blocks
leucine-rich, NES-mediated protein export (15, 37, 52). Simi-
larly to normal cells, export of human RPS6 was controlled by
the CRM1-mediated export pathway in PEL cells and in the
KSHV-infected TIVE L1 endothelial cells (data not shown).
This verifies that RPS6 is localized to the nucleus as part of its
normal maturation pathway. RPS6 is phosphorylated by p70S6
kinase, which in turn is mTOR dependent. However, RPS6 can
also be phosphorylated by other kinases such as p90S6 kinase.
Surprisingly, RPS6 phosphorylation does not affect overall
translation efficiency or the rate of RPS6 incorporation into
polyribosomes (66). Chemical inhibition of RPS6 phosphory-
lation (e.g., by mTOR inhibitors) does not result in wide-
spread, indiscriminate translational arrest or cell death.
Whether RPS6 phosphorylation plays a role in ribosome se-
lectivity for specific mRNAs (27) is subject to further study.
We predict that the significance of the LANA-RPS6 and
LANA-ribosomal protein interactions will reveal itself in due
time, analogous to the Hdm2-ribosome interactions. The first
demonstration that Hdm2 bound a ribosomal protein was pub-
lished in 1994 (47). Subsequently, it was shown that Hdm2
interacts with L11 and/or L23 (10, 82), establishing a tight
linkage between Hdm2, p53, and ribosome biogenesis. Re-
cently, it has become well established that Hdm2 and p53 are
sensors for ribosomal stress and ribosomal function (22). As a
fraction of LANA is associated with both p53 and Hdm2 (9,
67), this provides a mechanism for KSHV to manipulate cel-
lular ribosomal biogenesis and the stress signals that may orig-
inate from it for the purpose of latent viral persistence.
What could be the function of the LANA-RPS6 interaction,
and what is its significance? We noticed that phosphorylated
RPS6 in the nucleus of KSHV-infected cells was shielded from
the effect of rapamycin in L1 TIVE cells (unpublished obser-
vation). Rapamycin treatment effectively inhibits phosphoryla-
tion of RPS6 by p70S6K1 as well as p70S6K1 (42, 55, 69);
however, phosphorylation by p90S6K is not inhibited. Further-
more, p70S6K2 is cytoplasmic as well as nuclear and can even
be centrosome associated in mammalian cells (63). It is thus
conceivable that LANA may promote the phosphorylation of
RPS6 by centromeric p70S6K2, which in turn increases the
nuclear functionality of RPS6, perhaps during mitosis. It is
during mitosis, when the nuclear envelope breaks down, that
LANA decorates host chromosomes and that its function is
most crucial for viral episome segregation. The discovery of the
mTOR/S6K/S6 signaling arm taught us that the ribosomal pro-
teins are not mere building blocks of ribosomes, but may have
multiple functions in themselves and may be independent of
steady-state protein translation.
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